SafeStitch and TransEnterix set for merger; GenMark wants $75M in amped-up offering;

@FierceMedDev: Bard's fate hangs with jury in latest vaginal mesh lawsuit. Article | Follow @FierceMedDev

@DamianFierce: Quintiles is buying Novella with its eye on emerging biotechs. News from | Follow @DamianFierce

@MarkHFierce: For LumiQuick, is it another case of regulators trying to assert control over a surging Dx industry? Item | Follow @MarkHFierce

> SafeStitch Medical and TransEnterix have signed a deal to merge their operations. Report

> GenMark Diagnostics ($GNMK) is upsizing its previously announced stock offering, now seeking about $75 million through the sale of 7.6 million shares. News

> Patients with mitral regurgitation live longer if they get immediate surgery instead of waiting until the condition advances and requires a replacement heart valve, according to a new study. Article

> PerkinElmer has launched a prenatal test for early onset preeclampsia. Release

> New Jersey's Precision Spine has signed a deal with Japan's Mizuho Ikakogyo to get its devices distributed in the country. More

> Pathogenica gained a CE mark in Europe for its new diagnostic kit for hospital-associated infections. Item

Biotech News

@FierceBiotech: FDA's former IT boss nails down industry gig. Report from | Follow @FierceBiotech

@JohnCFierce: MannKind soars after inhaled Afrezza delivers positive PhIII results. Report | Follow @JohnCFierce

@RyanMFierce: Fate Therapeutics, founded by stem cell experts, targets $69 million IPO. Article | Follow @RyanMFierce

> The hottest disease field for biotech startups and M&A might surprise you. More

> Report: Novartis puts a $10B cap on acquisition targets, but steers clear of Onyx. Article

> Industry Voices: The man who cured aging? Article

Pharma News

@FiercePharma: With Pfizer, Novartis out, Amgen faces 1 possible rival for Onyx, per Bloomberg: AstraZeneca. Article | Follow @FiercePharma

@EricPFierce: India's Aurobindo buys, boosts capacity in sterile injectables, a hot market. Story from | Follow @EricPFierce

@CarlyHFierce: Here's the release on Boehringer earnings - BI says Pradaxa, Trajenta, Spiriva driving growth. Release | Follow @CarlyHFierce

> Tivicay marks beginning of end in growth of HIV branded market, EP says. Story

> China sales rep says Novartis ordered her to bribe doctors. Report

> New Novartis chair Reinhardt embarks on strategic review. Are divestments next? More

Drug Delivery News

@MichaelGFierce: Virus-killing nanoviricides win orphan status for dengue fever. Story | Follow @MichaelGFierce

> Receptor-targeted antifolate drugs yield fewer side effects. More

> Bind files $80M IPO to support PhII nanotech cancer drug delivery. News

> 'Smart' DNA-based nanomeds self-assemble to release cancer drug. Story

> MannKind's inhaled insulin delivery tech passes PhIII trial. Article

> NanoMedical Systems snags $2.3M to develop drug-releasing implant. Item

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.